Product Pipeline

Our Goal is to make a Significant Impact on Metabolic Diseases

We are maximizing the potential of innovative molecules to make an impact on metabolic diseases, particularly in type 2 diabetes and are committed to developing new, safe and effective treatment options for patients suffering from type 2 diabetes and other metabolic disorders.

Why Our Focus is on Type 2 Diabetes

Type 2 diabetes is one of the world's major health concerns and its incidence is growing rapidly. It is the most common form of diabetes, affecting about 90% of diabetic patients.

The Challenge with the Current Standard of Care

The current standard of care for the majority of patients is limited by the fact that none of the available therapeutic options is satisfactorily effective in controlling the disease and marketed therapeutics are associated with safety and tolerability side effects as well as weight gain and hypoglycemia.

Candidate & Indication MoA Development Stage
Discovery Preclinical Phase 1 Phase 2b Phase 3
Imeglimin Type 2 Diabetes
Japan Development
Mitochondrial bioenergetics enhancer
Discovery complete
Preclinical complete
Phase 1 complete
Phase 2b complete
Phase 3 in progress
Imeglimin Type 2 Diabetes
EU & US Development
Mitochondrial bioenergetics enhancer
Discovery complete
Preclinical complete
Phase 1 complete
Phase 2b in progress
Phase 3 not started
PXL770 Metabolic Diseases, Type 2 Diabetes Direct AMPK activator
Discovery complete
Preclinical complete
Phase 1 in progress
Phase 2b not started
Phase 3 not started
PXL007 (EYP001)1 Hepatitis B FxR Agonist
Discovery complete
Preclinical complete
Phase 1 in progress
Phase 2b not started
Phase 3 not started

Discovery Programs

#2 Type 2 Diabetes Oral GLP-1 agonist
Discovery in progress
Preclinical not started
Phase 1 not started
Phase 2b not started
Phase 3 not started
#3 Type 2 Diabetes GK activator
Discovery in progress
Preclinical not started
Phase 1 not started
Phase 2b not started
Phase 3 not started
#4 Type 2 Diabetes 11 beta HSD1 inhibitor
Discovery in progress
Preclinical not started
Phase 1 not started
Phase 2b not started
Phase 3 not started
  1. Enyo Pharmaceuticals is advancing EYP001 through a licensing agreement with Poxel.

Imeglimin

Imeglimin is the first orally-available anti-diabetes drug candidate that simultaneously targets all three key organs of diabetes, which includes the pancreas, liver, and muscles.

U.S. and E.U.

The U.S. and EU market provides a ~$32B* market opportunity where we continue to strengthen Imeglimin's differentiated product profile for the Phase 3 program.

View Additional Information

Japan/Asia

The steady growing, ~$4B* Japanese diabetes market offers a unique value creation opportunity.  In Japan and Asia, Sumitomo Dainippon Pharma is our strategic partner for Imeglimin. For Japan, Poxel and Sumitomo Dainippon Pharma are jointly conducting the Phase 3 TIMES program for Imeglimin, which is being funded by Sumitomo Dainippon Pharma, and Sumitomo Dainippon Pharma will commercialize the product for this market. In China, South Korea, Taiwan and nine other Southeast Asian countries including Indonesia, Vietnam, Thailand, Malaysia, the Philippines, Singapore, Myanmar, Cambodia, and Laos, Sumitomo Dainippon Pharma will be solely responsible for the development and commercialization of Imeglimin.

View Additional Information

*Decision Resources, September 2014

PXL770

PXL770 directly activates adenosine monophosphate-activated protein kinase (AMPK), an enzyme that controls whole-body energy metabolism and plays an important role in metabolic disorders, including liver and kidney diseases, as well as in the management of diabetes.

View Additional Information

PXL007 (EYP001)

Through a licensing agreement with Enyo Pharmaceuticals, EYP001, an FXR agonist, is in a Phase 1 study for the treatment of Hepatitis B.

View Additional Information

Publications

Review our scientific publications, as well as posters and presentations.

View Publications

Sign up for email alerts

Be the first to receive breaking news

Sign up today